Scientists at Britain’s Oxford University started a clinical trial to investigate the effects of an HIV medicine and a steroid drug in UK patients admitted to hospital with COVID-19 caused by the new coronavirus.
As part of strategic refocusing, AstraZeneca sold the rights to two cancer drugs in several countries in Europe, Africa and other countries to Juvisé Pharmaceuticals.
Vertex Pharmaceuticals Inc. priced the company’s FDA-approved Trikafta, a three-drug combination for cystic fibrosis, at $311,503 per year.
Indianapolis-based Eli Lilly announced the closing of the company’s Surrey, U.K.-based Erl Wood neuroscience research center by the end of 2020, affecting 270 staffers.
Novartis AG’s gene therapy Luxturna for blindness is recommended for use on England’s public health service, according to the country’s healthcare cost-effectiveness watchdog NICE.
Opioid use has reached crisis proportions not only in the United States but also in Canada and some European countries, as prescription opioid painkillers have become much more common, the OECD club of wealthy nations said.
England’s National Health Service reached a deal to pay for U.S. drugmaker Biogen Inc.’s expensive spinal muscle atrophy treatment Spinraza.
Novartis’ Kymriah won the blessing of health authorities in England for adult lymphoma patients, the Swiss drugmaker said, reversing the 2018 rejection of the cell therapy.
A new report indicates that the so-called “Brexit” will have a negative impact on healthcare in the United Kingdom.
According to a drug shortage list provided by the U.S. Food and Drug Administration, there have been more than 100 drugs that have faced shortages during 2018.